Allgenesis Phase 2 DME Trial Support
Diabetic Macular Edema (DME)
Phase 2Active
Key Facts
About Voxeleron
Voxeleron is a technology and services company that leverages artificial intelligence and machine learning to analyze ophthalmic images for clinical research. Its core platform, iNebula, facilitates the management, analysis, and sharing of complex imaging datasets, aiming to accelerate ophthalmic drug development by providing standardized, device-agnostic insights. Recently acquired by Voiant, Voxeleron operates as a strategic component within a larger clinical trial imaging ecosystem, serving pharmaceutical sponsors and research organizations. The company is ISO 13485:2016 certified, indicating a quality management system for medical devices.
View full company profileTherapeutic Areas
Other Diabetic Macular Edema (DME) Drugs
| Drug | Company | Phase |
|---|---|---|
| UBX1325 (foselutoclax) | Unity Biotechnology | Phase 2b |
| CLS-AX | Clearside Biomedical | Preclinical |
| OCS-01 | Oculis | Phase 3 |
| Oral K9 | Inflammasome Therapeutics | Phase I |
| Ixoberogene soroparvovec (Ixo-vec) | Adverum Biotechnologies | Phase 2 |
| Avoralstat | BioCryst Pharmaceuticals | Phase 2 |
| DURAVYU™ (EYP-1901) | EyePoint Pharmaceuticals | Phase 3 |
| Sozinibercept (OPT-302) | Opthea | Phase 2 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg) | Outlook Therapeutics | Phase 3 |